Rock Springs Capital Management LP Adaptimmune Therapeutics PLC Transaction History

Rock Springs Capital Management LP

$2.94 Billion
Q3 2024

A detailed history of Rock Springs Capital Management LP transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Rock Springs Capital Management LP holds 2,425,468 shares of ADAP stock, worth $1.55 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

2,425,468

Previous 2,425,468 -0.0%

Holding current value

$1.55 Million

Previous $2.38 Million 3.03%

% of portfolio

0.08%

Previous 0.07%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.43 - $0.79 $155,822 - $286,277	-362,377 Reduced 13.0%	2,425,468 $1.92 Million
Q1 2023 May 15, 2023	BUY	$1.06 - $2.16 $117,987 - $240,427	111,309 Added 4.16%	2,787,845 $3.04 Million
Q4 2022 Feb 14, 2023	BUY	$1.05 - $2.53 $334,941 - $807,049	318,992 Added 13.53%	2,676,536 $3.91 Million
Q2 2022 Aug 15, 2022	BUY	$1.33 - $2.28 $80,265 - $137,598	60,350 Added 2.63%	2,357,544 $4.01 Million
Q1 2022 May 16, 2022	BUY	$1.73 - $4.06 $141,178 - $331,320	81,606 Added 3.68%	2,297,194 $4.73 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $5.68 $90,300 - $146,544	25,800 Added 1.18%	2,215,588 $8.31 Million
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $2.22 Million - $4.11 Million	644,788 Added 41.73%	2,189,788 $11.3 Million
Q4 2020 Feb 16, 2021	SELL	$4.0 - $9.2 $1.77 Million - $4.07 Million	-441,910 Reduced 22.24%	1,545,000 $8.33 Million
Q2 2020 Aug 14, 2020	BUY	$2.58 - $12.1 $2.03 Million - $9.52 Million	786,910 Added 65.58%	1,986,910 $19.9 Million
Q1 2020 May 15, 2020	BUY	$1.2 - $4.52 $480,000 - $1.81 Million	400,000 Added 50.0%	1,200,000 $3.26 Million
Q4 2019 Feb 14, 2020	SELL	$0.72 - $1.43 $54,000 - $107,250	-75,000 Reduced 8.57%	800,000 $960,000
Q2 2019 Aug 14, 2019	BUY	$3.23 - $5.41 $242,250 - $405,750	75,000 Added 9.38%	875,000 $3.52 Million
Q1 2019 May 15, 2019	BUY	$3.63 - $6.06 $181,500 - $303,000	50,000 Added 6.67%	800,000 $3.44 Million
Q2 2018 Aug 14, 2018	SELL	$10.42 - $13.74 $1.3 Million - $1.72 Million	-125,000 Reduced 14.29%	750,000 $8.9 Million
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $4.31 Million - $7.81 Million	875,000	875,000 $7.17 Million

Others Institutions Holding ADAP

# of Institutions

Shares Held

150M

Call Options Held

60.8K

Put Options Held

5.8K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $105M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.

Account

Rock Springs Capital Management LP Adaptimmune Therapeutics PLC Transaction History